FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Orlinger Klaus

2. Date of Event Requiring Statement (MM/DD/YYYY)
4/17/2019 

3. Issuer Name and Ticker or Trading Symbol

HOOKIPA Pharma Inc. [HOOK]

(Last)        (First)        (Middle)

C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
Sr. VP, Research /

(Street)

NEW YORK, NY 10118       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)     (1) 12/31/2026   Common Stock   7358   $0.10   D    
Stock Option (Right to Buy)     (2) 12/31/2026   Common Stock   2282   $0.10   D    
Stock Option (Right to Buy)     (3) 12/31/2026   Common Stock   15101   $0.10   D    
Stock Option (Right to Buy)     (4) 12/31/2026   Common Stock   23286   $0.10   D    

Explanation of Responses:
(1)  This option is fully vested and exercisable.
(2)  This option is fully vested and exercisable.
(3)  25% of this option vested and became exercisable on January 1, 2018, with the remainder vesting in 12 equal quarterly installments thereafter.
(4)  25% of this option vested and became exercisable on December 1, 2018, with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:
Exhibit 24.1: Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Orlinger Klaus
C/O HOOKIPA PHARMA INC.
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240
NEW YORK, NY 10118


Sr. VP, Research

Signatures
/s/ Klaus Orlinger 4/17/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more HOOKIPA Pharma Charts.
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more HOOKIPA Pharma Charts.